2024
Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction
Yang M, Kondo T, Talebi A, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction. European Journal Of Heart Failure 2024, 26: 1524-1538. PMID: 38700986, DOI: 10.1002/ejhf.3263.Peer-Reviewed Original ResearchConceptsVisual analogue scaleEjection fractionEQ-5D-5L visual analogue scaleHealth-related quality of lifeIndex scorePatient-level pooled analysisComposite of cardiovascular deathQuality of lifeSafety of dapagliflozinEffects of dapagliflozinReduced ejection fractionAssociated with better outcomesPrevalence of comorbiditiesEuroQol 5-dimension questionnaireMeasures of health-related quality of lifePatient self-reportDAPA-HFWorsening HFVAS scoreClinical characteristicsAtrial fibrillationComposite outcomeHeart failurePooled analysisAnalogue scale
2023
Effects of Dapagliflozin in Patients in Asia A Post Hoc Subgroup Analysis From the DELIVER Trial
Wang X, Lam C, Vaduganathan M, Kondo T, Yang M, Han Y, Pham V, Chiang C, Kitakaze M, Miao Z, Jhund P, Desai A, Inzucchi S, de Boer R, Martinez F, Kosiborod M, Hernandez A, Claggett B, Langkilde A, McMurray J, Solomon S. Effects of Dapagliflozin in Patients in Asia A Post Hoc Subgroup Analysis From the DELIVER Trial. JACC Asia 2023, 4: 108-118. PMID: 38371292, PMCID: PMC10866733, DOI: 10.1016/j.jacasi.2023.10.005.Peer-Reviewed Original ResearchEffects of dapagliflozinHeart failureDELIVER trialClinical characteristicsRisk of primary composite outcomesRate of drug discontinuationLeft ventricular ejection fractionRisk of all-cause mortalityRisk of CV deathEfficacy of dapagliflozinWorsening HF eventsVentricular ejection fractionHistory of myocardial infarctionSerious adverse eventsPrimary composite outcomeAll-cause mortalityClinically relevant characteristicsDrug discontinuationEjection fractionAdverse eventsCV deathTreatment armsComposite outcomeSubgroup analysisPrimary outcomeEfficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER
Kondo T, Vaduganathan V, Hernandez A, Lam C, Inzucchi S, Martinez F, De Boer R, Kosiborod M, Desai A, Kober L, Ponikowski P, Sabatine M, Shah S, Solomon S, Mcmurray J. Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER. European Heart Journal 2023, 44: ehad655.979. DOI: 10.1093/eurheartj/ehad655.979.Peer-Reviewed Original ResearchLeft ventricular ejection fractionSafety of dapagliflozinHeart failureDAPA-HFPrimary outcomeEjection fractionMean baseline LVEFBaseline left ventricular ejection fractionPatient-level pooled analysisBackground clinical characteristicsBenefit of dapagliflozinEfficacy of dapagliflozinElevated natriuretic peptidesNatriuretic peptide levelsEffect of dapagliflozinMineralocorticoid receptor antagonistsVentricular ejection fractionCardiovascular deathClinical characteristicsDiscontinuation ratesStandard careHazard ratioPatient characteristicsNatriuretic peptidePooled analysisEfficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure
Kondo T, Wang X, Yang M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Langkilde A, Petersson M, Zaozerska N, Bachus E, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. Journal Of The American College Of Cardiology 2023, 82: 1014-1026. PMID: 37610398, DOI: 10.1016/j.jacc.2023.05.056.Peer-Reviewed Original ResearchConceptsSafety of dapagliflozinHeart failurePrimary outcomeEjection fractionPatient-level pooled analysisBenefit of dapagliflozinEfficacy of dapagliflozinReduced ejection fractionEffect of dapagliflozinDAPA-HFCardiovascular deathClinical characteristicsDiscontinuation ratesPatient characteristicsPooled analysisDapagliflozinPatientsBackground treatmentEvent ratesInhibitor efficacyEfficacyGeographic regionsOutcomesTreatmentPrevious reports